CANF Stock Soars 20% on Positive Mid-Stage Pancreatic Cancer Data

Core Insights - Can-Fite BioPharma (CANF) shares increased by 20.4% following the announcement of positive top-line results from a mid-stage study of its investigational candidate, namodenoson, for patients with advanced pancreatic ductal adenocarcinoma (PDAC) who had previously undergone systemic therapies [1][4]. Study Results - The phase IIa study of namodenoson included 20 patients with advanced PDAC who had received at least one prior line of therapy, indicating a high-risk group with diverse performance status and advanced metastatic disease [2]. - The study successfully met its primary safety endpoint, showing strong tolerability in a heavily pretreated population of PDAC patients, with no new safety concerns reported [3][4]. Survival Data - Secondary endpoints evaluated included overall survival and progression-free survival, with ongoing survival monitoring indicating that approximately one-third of the enrolled patients were still alive at the data cutoff [5][6]. - The company plans to present updated survival findings at upcoming scientific conferences as additional data matures [6]. Broader Clinical Pipeline - Besides PDAC, Can-Fite is also assessing namodenoson in a late-stage study for advanced liver cancer (hepatocellular carcinoma) and in a mid-stage study for metabolic-associated steatohepatitis [7]. - The company's clinical pipeline includes its lead candidate, piclidenoson, which is under evaluation in a pivotal late-stage study for psoriasis [7].